Serum Neutralizing and Enhancing Effects on African Swine Fever Virus Infectivity in Adherent Pig PBMC

Viruses. 2022 Jun 9;14(6):1249. doi: 10.3390/v14061249.

Abstract

African swine fever virus (ASFV) causes hemorrhagic fever with mortality rates of up to 100% in domestic pigs. Currently, there are no commercial vaccines for the disease. Only some live-attenuated viruses have been able to protect pigs from ASFV infection. The immune mechanisms involved in the protection are unclear. Immune sera can neutralize ASFV but incompletely. The mechanisms involved are not fully understood. Currently, there is no standardized protocol for ASFV neutralization assays. In this study, a flow cytometry-based ASFV neutralization assay was developed and tested in pig adherent PBMC using a virulent ASFV containing a fluorescent protein gene as a substrate for neutralization. As with previous studies, the percentage of infected macrophages was approximately five time higher than that of infected monocytes, and nearly all infected cells displayed no staining with anti-CD16 antibodies. Sera from naïve pigs and pigs immunized with a live-attenuated ASFV and fully protected against parental virus were used in the assay. The sera displayed incomplete neutralization with MOI-dependent neutralizing efficacies. Extracellular, but not intracellular, virions suspended in naïve serum were more infectious than those in the culture medium, as reported for some enveloped viruses, suggesting a novel mechanism of ASFV infection in macrophages. Both the intracellular and extracellular virions could not be completely neutralized.

Keywords: African swine fever virus (ASFV); extracellular virions; flow cytometry; hyperimmune serum; monocyte-derived macrophage; serum-enhanced virus infection; virus neutralization.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • African Swine Fever Virus* / genetics
  • African Swine Fever*
  • Animals
  • Leukocytes, Mononuclear
  • Sus scrofa
  • Swine
  • Viral Proteins / genetics

Substances

  • Viral Proteins

Grants and funding

The data used in this study are derived from research primarily funded by an interagency agreement with the Science and Technology Directorate of the U.S. Department of Homeland Security under award No. 70RSAT19KPM000110 and The U.S. Department of Agriculture, Agricultural Research Service-CRIS project 1940-32000-060-00D. This research was also supported in part by an appointment to the Plum Island Animal Disease Center Research Participation Program administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy (DOE) and the U.S. Department of Agriculture. ORISE is managed by Oak Ridge Associated Universities under DOE contract number DE-SC0014664.